# Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX

> **NCT02425683** · PHASE2 · TERMINATED · sponsor: **US Oncology Research** · enrollment: 24 (actual)

## Conditions studied

- Colorectal Neoplasms
- Adenocarcinoma of the Colon
- Adenocarcinoma of the Rectum

## Interventions

- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT02425683
- **Lead sponsor:** US Oncology Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03-26
- **Primary completion:** 2017-09-21
- **Final completion:** 2017-09-21
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** insufficient accrual
- **Last updated:** 2020-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02425683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02425683, "Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02425683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*